Bortezomib induced a phrenic palsy in a multiple myeloma patient.
Vitalie
V
Nizeica
Philippe
P
Collet
Hubert
H
Marotte
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000627:therapeutic use; D001897:Boronic Acids / Q000008:administration & dosage / Q000009:adverse effects*; D000069286:Bortezomib; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D003929:Diabetic Neuropathies / Q000175:diagnosis; D003937:Diagnosis, Differential; D004164:Diphosphonates / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D009101:Multiple Myeloma / Q000150:complications / Q000188:drug therapy*; D009408:Nerve Compression Syndromes / Q000175:diagnosis; D009437:Neuralgia / Q000139:chemically induced / Q000188:drug therapy; D010791:Phrenic Nerve / Q000187:drug effects / Q000503:physiopathology; D011241:Prednisone / Q000008:administration & dosage; D000069583:Pregabalin; D011480:Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D011719:Pyrazines / Q000008:administration & dosage / Q000009:adverse effects*; D012133:Respiratory Paralysis / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D000077211:Zoledronic Acid; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives / Q000627:therapeutic use
D050071:Bone Density Conservation Agents; D001897:Boronic Acids; D004164:Diphosphonates; D007093:Imidazoles; D011480:Protease Inhibitors; D011719:Pyrazines; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid; D000069286:Bortezomib; D000077211:Zoledronic Acid; D008558:Melphalan; D011241:Prednisone